Skip to content
i2E
  • Programs
    • For Startups
      • E3
      • Bridge2
      • OCN
    • For Students
      • Entrepreneur’s Cup
    • For Corporations
    • For Investors
  • Client Portfolio
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Events
  • Contact
  • Media
  • Programs
    • For Startups
      • E3
      • Bridge2
      • OCN
    • For Students
      • Entrepreneur’s Cup
    • For Corporations
    • For Investors
  • Client Portfolio
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Events
  • Contact
  • Media
Search

Grant supports research for sickle cell pill

Get in Touch

By Sarah Terry-Cobo
Courtesy of The Journal Record 

OKLAHOMA CITY – Robert Broyles received $218,000 to advance his business, and he aims to turn it into more than $1 million. If he is successful, the chief scientific officer and founder of EpimedX could also help thousands of people who are suffering from a debilitating genetic mutation.

Broyles received the grant from the National Institutes of Health to advance his research on sickle cell anemia.

He aims to create a pill that would effectively cure the condition, which causes a deformation in red blood cells that can lead to pain and organ damage. The treatment, known as EDX-17, wouldn’t change the underlying mutated genes. However, Broyles said the treatment will activate a fetal gene that lies dormant and suppresses symptoms.

EpimedX co-founder Robert Broyles/Courtesy photo
EpimedX co-founder Robert Broyles/Courtesy photo

His company’s research has found a compound created by plants that he believes activates the gene. He said the NIH money will help him complete proof-of-concept work in animal models. He said he’s confident the compound is safe because it’s sprayed on food crops for agricultural purposes. The Environmental Protection Agency has data showing it is safe, he said.

Since he founded the company in 2011, he has raised nearly $1 million from investors and grants from Oklahoma City-based Innovation to Enterprise, or i2E Inc. In April 2015, he will apply for more money from the NIH Small Business Innovation Research program to help the company prepare for clinical trials.

He will seek $1.5 million to perform additional safety tests in Food and Drug Administration-certified laboratories, which are very expensive, Broyles said. He said those safety tests will help advance the research to clinical trials.

EpimedX isn’t the only company in the Oklahoma City metro working on a treatment for the disease. Selexys Pharmaceuticals has advanced its sickle cell treatment to phase-two clinical trials with the FDA.

Though Selexys’ research is for a different type of treatment, it helped show there was investor interest, Broyles said. Rick Rainey, venture adviser and assistant director for i2E’s Oklahoma SBIR Collaborative Resource project, agreed. Rainey said his group helped Broyles write grants to obtain funding.

“Selexys’ investor success gives us confidence that a company such as EpimedX would have a reasonable shot at that as well,” Rainey said.

Because Broyles’ therapeutic molecule has such a low toxicity, Rainey said he expects the research to move smoothly through the drug-testing process.

If Broyles continues to receive more grant funding, it will allow him to hire more researchers to work in his Oklahoma City lab. He said he’s confident there will be a market for the drug because the pill wouldn’t require expensive gene therapy treatments at medical centers.

“Because the safety of the molecule looks good and it is easy to manufacture the substance, it will ultimately be available in remote areas where gene therapy will never reach,” Broyles said.

Read the story at the Journal Record website (subscription required)

More News

Loading...
Blog, Featured, News
12.16.24

MidAmerica and i2E Announce Award Winners

Read more
Blog, Featured, News
11.21.24

i2E & Plains Ventures Surpasses $100M Milestone in Total Investments

Read more
Blog
09.30.24

i2E Receives 2024 Excellence in Economic Development Award from IEDC

Read more
Blog
06.18.24

Bridge2 Demo Day Returns, Highlighting Promising Oklahoma Startups

Read more
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
05.13.24

Student Entrepreneurs Triumph at 20th Anniversary Entrepreneur’s Cup, Winning $158,000 in Prizes

Read more
Default Featured Image
Blog, Entrepreneur's Cup News
04.24.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Jessica Kinsey

Read more
Default Featured Image
Blog, Entrepreneur's Cup News
04.23.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Nathan Fountain

Read more
Default Featured Image
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
04.23.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Srijita Ghosh

Read more
Default Featured Image
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
04.18.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – MaxQ

Read more
Blog, i2E
01.30.24

i2E Celebrates Success of Inaugural Bridge2 Demo Day

Read more
Blog, i2E, News
12.18.23

i2E and MidAmerica Industrial Park announce award winners for high school entrepreneurship program

Read more
Blog, i2E
12.13.23

Entrepreneur’s Cup Marks 20 Years: Reimagined Competition and Brand – Same Entrepreneurial Spirit

Read more
i2E

Oklahoma City Office

201 Robert S Kerr Ave, Suite 600
Oklahoma City, OK 73102
+1 (405) 235.2305

Tulsa Office

12 N. Cheyenne Ave, Suite 112
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources
  • Funding
  • Venture Advisory

© 2025 i2E Privacy Policy

Follow us:

Linkedin Twitter Facebook Instagram Youtube

Programs

  • For Startups
    • E3
    • Bridge2
    • OCN
  • For Students
    • Entrepreneur’s Cup
  • For Corporations
  • For Investors
  • For Startups
    • E3
    • Bridge2
    • OCN
  • For Students
    • Entrepreneur’s Cup
  • For Corporations
  • For Investors
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Events
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E